Pre-clinical

AL-309

AL-309 is in preclinical development and has demonstrated efficacy in animal models related to neuropathy, Alzheimer's disease and fetal alcohol syndrome.  The most likely human clinical application for this product candidate is peripheral neuropathy, a group of debilitating and painful conditions suffered by millions of people and resulting from nerve damage for which there is currently no effective treatment available.  Among the major causes of neuropathy are diabetes and cancer chemotherapy.